NF-κB-mediated chemoresistance can be classified into two types: primary, driven by intrinsic NF-κB activation within cancer cells, and acquired, triggered by chemotherapeutic agents such as Cisplatin, Carboplatin, Paclitaxel, and Doxorubicin, which activate downstream NF-κB signaling pathways [59]​. The gene discussed is NFKB1; the disease is cancer.